Cantor Fitzgerald assumed coverage of Legend Biotech (LEGN) with an Overweight rating and price target of $66, up from $55. The firm sees 88% potential upside from the current price. The company’s Carvykti has “rapidly become” the most successful CAR T-cell therapy on the market. the analyst tells investors in a research note. Cantor believes Carvykti is positioned o be a multi-billion-dollar franchise.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech price target raised to $78 from $77 at JPMorgan
- Legend Biotech Appoints Carlos Santos as CFO to Drive Financial Strategy
- Legend Biotech appoints Santos as Chief Financial Officer
- Legend Biotech’s Earnings Call: Growth and Success
- Legend Biotech price target raised to $77 from $75 at RBC Capital